Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Influence of CYP2C19 Polymorphism on Antiplatelet Effects and Clinical Outcomes in Non-acute Stroke Patients Treated With Clopidogrel: The Contribution of Genetic Analysis to the Efficacy of Clopidogrel (Cognac) Study

NCT02711410 is registered in ClinicalTrials.gov with National Cerebral and Cardiovascular Center, Japan as lead sponsor.

NCT NCT02711410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02711410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Influence of CYP2C19 Polymorphism on Antiplatelet Effects and Clinical Outcomes in Non-acute Stroke Patients Treated With Clopidogrel: The Contribution of Genetic Analysis to the Efficacy of Clopidogrel (Cognac) Study
Lead sponsor
National Cerebral and Cardiovascular Center, Japan
Phase
Observational
Overall status
Completed
Start date
October 31, 2009
Completion date
October 31, 2015
Enrollment
518 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

platelet aggregation inhibitors